Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy BioLineRx stock
Learn how to easily invest in BioLineRx stock.
BioLineRx Ltd is a biotechnology business based in the US. BioLineRx shares (BLRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioLineRx employs 38 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in BioLineRx
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BLRX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
BioLineRx stock price (NASDAQ: BLRX)Use our graph to track the performance of BLRX stocks over time.
BioLineRx shares at a glance
|Latest market close||$0.90|
|52-week range||$0.84 - $3.15|
|50-day moving average||$1.49|
|200-day moving average||$1.60|
|Wall St. target price||$10.75|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.47|
Buy BioLineRx shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy BioLineRx stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioLineRx price performance over time
|1 week (2022-09-23)||-5.68%|
|1 month (2022-08-30)||-40.66%|
|3 months (2022-06-30)||-30.00%|
|6 months (2022-03-30)||-46.02%|
|1 year (2021-09-30)||-67.42%|
|2 years (2020-09-30)||-45.37%|
|3 years (2019-09-30)||2.64|
|5 years (2017-09-29)||1.12|
Is BioLineRx stock undervalued or overvalued?
Valuing BioLineRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLineRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioLineRx's PEG ratio
BioLineRx's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLineRx's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||$0|
|Return on assets TTM||-20.81%|
|Return on equity TTM||-34.33%|
|Market capitalisation||$54.1 million|
TTM: trailing 12 months
BioLineRx share dividends
We're not expecting BioLineRx to pay a dividend over the next 12 months.
Have BioLineRx's shares ever split?
BioLineRx's shares were split on a 1:15 basis on 15 July 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLineRx shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for BioLineRx shares which in turn could have impacted BioLineRx's share price.
BioLineRx share price volatility
Over the last 12 months, BioLineRx's shares have ranged in value from as little as $0.84 up to $3.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLineRx's is 1.4072. This would suggest that BioLineRx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioLineRx Ltd. , a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx in the news
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
BioLineRx Announces $15 Million Registered Direct Offering
BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer
Frequently asked questionsWhat percentage of BioLineRx is owned by institutions?
Currently 5.415% of BioLineRx shares are held by institutions. How many people work for BioLineRx?
Latest data suggests 38 work at BioLineRx. When does the fiscal year end for BioLineRx?
BioLineRx's fiscal year ends in December. Where is BioLineRx based?
BioLineRx's address is: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 What is BioLineRx's ISIN number?
BioLineRx's international securities identification number is: US09071M2052 What is BioLineRx's CUSIP number?
BioLineRx's Committee on Uniform Securities Identification Procedures number is: 09071M106
More guides on Finder
Alternatives to Webull
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Best renewable energy stocks for 2022
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
The best dividend stocks for 2022
Our list of 10 dividend stocks to watch in 2022.
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Ask an Expert